AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04069351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-calorie mass gainer supplement
Description: A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
Study NCT04069351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: All participants will complete a 6-week supervised resistance training program.
Study NCT03283280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ever X Posterior
Description: Resin composite restoration can be made as a direct onlay
Study NCT03283280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ever X Posterior
Description: Resin composite restoration can be made as a direct onlay
Study NCT02652650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol
Description: Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
Study NCT02652650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
Study NCT02652650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
Study NCT01549782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin and Fructo-oligosaccharide
Description: 6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
Study NCT01549782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Description: 6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
Study NCT02748837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Study NCT04890678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22 residentsat risk for PU development
Description: mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.
Study NCT04890678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18 residents at least one PU category III-IV in the sacral area
Description: mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed.
Study NCT03690141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
Study NCT01243541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Patients wear an Elasto-Gel cold glove and sock
Study NCT01243541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01243541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01243541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
Study NCT01243541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
Study NCT00770237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cues
Description: In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
Study NCT00770237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Cues
Description: In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
Study NCT00041067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00041067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00041067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00041067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT01266525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR110894
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Study NCT01266525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for SAR110894)
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Study NCT01266525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion
Study NCT01266525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion
Study NCT01126151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent handbook
Description: parent handbook
Study NCT00141323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.5 mg once per day, orally
Study NCT00141323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00141323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.25 mg once per day, orally
Study NCT04258527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
Study NCT04646512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taurine group and exercise and placebo group and exercise
Description: Both groups supplemented with taurine and / or placebo will perform physical training.
Study NCT04646512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Taurine group and exercise and placebo group and exercise
Description: Both groups supplemented with taurine and / or placebo will perform physical training.
Study NCT04646512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical training with Deep Water Running
Description: There will be a physical training for eight weeks.
Study NCT04646512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training with Deep Water Running
Description: There will be a physical training for eight weeks.
Study NCT04239521 — intervention group
Intervention type: OTHER
Intervention: Exposure of interest (studies 2 & 3).
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
Study NCT01463384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 50mg, twice daily for 6 months.
Study NCT00874666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crushed garlic clove
Description: 1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
Study NCT00874666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: garlic powder tablet
Description: tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
Study NCT02379481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NS 550mg
Study NCT02379481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NS 1100mg
Study NCT02379481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
Study NCT00635726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
Study NCT02190669 — intervention group
Intervention type: OTHER
Intervention: exercise
Description: Sprinting, walking on a treadmill, and stationary bicycle riding
Study NCT02564939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: double-blind RCT
Study NCT02564939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: double-blind RCT
Study NCT01066468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec/Glivec
Study NCT01098136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Manual treatment of musculoskeletal complaints
Study NCT01098136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medical intervention
Description: Medical, physiotherapy
Study NCT01098136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional and alternative intervention
Description: Medical and alternative methods for treatment of pelvic pain syndromes
Study NCT02678416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen (Treatment A)
Description: Acetaminophen administered by intravenous (IV) infusion
Study NCT02678416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Acetaminophen (Treatment B)
Description: Acetaminophen administered by oral tablets
Study NCT02678416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Treatment C)
Description: Placebo administered by IV infusion or oral tablets
Study NCT02678416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morphine (Treatment D)
Description: Morphine administered by IV infusion
Study NCT01397864 — intervention group
Intervention type: DRUG
Intervention: rhC1INH or pdC1INH
Description: C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Study NCT04696991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The postpartum discharge education with PechaKucha Method.
Description: The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
Study NCT03500250 — intervention group
Intervention type: OTHER
Intervention: Post-Stroke Depression toolkit
Description: The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
Study NCT02257957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Study NCT02257957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care Hyaluronic acid eye drops
Description: : 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
Study NCT01938807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CareCoach mobile application to assist in diabetes management
Study NCT01938807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareCoach mobile application to assist in diabetes management
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
Description: 1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
Study NCT00356460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
Study NCT05208801 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Percutaneous injection
Description: A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
Study NCT05208801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal injection of morphine 400mcg
Study NCT05208801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine+Bupivacaine
Description: Intrathecal injection of 5mg of 0.5% bupivacaine chloride
Study NCT02345122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Mental Health Technician
Description: In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
Study NCT02345122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
Study NCT02073734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg/IV
Study NCT02073734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV
Study NCT02248220 — intervention group
Intervention type: DRUG
Intervention: Pramipexole
Study NCT03598322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 1mL injection
Description: Dextrose 1mL injection and hydrodissection for CTS
Study NCT03598322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose 2mL injection
Description: Dextrose 2mL injection
Study NCT03598322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose 4mL injection
Description: Dextrose 4mL injection
Study NCT00752622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
Study NCT00752622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks
Description: Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
Study NCT00752622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 7 mg/kg every 8 weeks
Description: Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
Study NCT02141542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT02141542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617